S&P Biotech ETF Harvest announced that on October 14, 2026, the fund's secondary market closing price was 1,544 yuan, and the reference net value of the fund share at the close was 1.4566 yuan. The transaction price in the secondary market was significantly higher than the reference net value of the fund share, showing a large premium. If the premium margin is not effectively reduced on October 15, 2026, the fund has the right to apply for measures such as temporary intraday suspension, extended suspension period, and continuous suspension of trading to warn of risks. Currently, the fund is operating normally, and there is no material information that should be disclosed but not disclosed.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.